Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/Db-β2m transgenic mice

Lior Carmon, Irene Bobilev-Priel, Baruch Brenner, Dimitry Bobilev, Adrian Paz, Erez Bar-Haim, Boaz Tirosh, Tirza Klein, Mati Fridkin, Francois Lemonnier, Esther Tzehoval, Lea Eisenbach*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

The human milk fat globule membrane protein BA46 (lactadherin) is highly overexpressed in human breast tumors, making it a potential target for tumor immunotherapy. We have identified BA46-derived peptides that contain the motif recognized by the MHC class I molecule HLA-A2.1 and that are processed and presented by human breast carcinoma cells. In mice lacking normal class I molecules but expressing an HLA-A2.1/Db-β2 microglobulin single chain (HHD mice), three peptides elicited specific CTL activity. Two of these peptides also stimulated cytotoxic activity in peripheral blood lymphocytes from HLA-A2.1-positive breast carcinoma patients. Adoptive transfer of HHD-derived bulk CTLs to nude mice bearing human breast carcinoma transplants reduced tumor growth. These peptides therefore represent naturally processed BA46-derived CTL epitopes that can be used in peptide-based antitumor vaccines.

Original languageEnglish
Pages (from-to)453-462
Number of pages10
JournalJournal of Clinical Investigation
Volume110
Issue number4
DOIs
StatePublished - Aug 2002

Fingerprint

Dive into the research topics of 'Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/Db-β2m transgenic mice'. Together they form a unique fingerprint.

Cite this